Wedbush Has Pessimistic Outlook of Ardelyx FY2025 Earnings

Ardelyx, Inc. (NASDAQ:ARDX - Free Report) - Investment analysts at Wedbush decreased their FY2025 earnings per share (EPS) estimates for Ardelyx in a research report issued on Wednesday, April 16th. Wedbush analyst L. Chico now anticipates that the biopharmaceutical company will post earnings per share of ($0.26) for the year, down from their prior forecast of ($0.25). The consensus estimate for Ardelyx's current full-year earnings is ($0.18) per share. Wedbush also issued estimates for Ardelyx's Q1 2026 earnings at ($0.03) EPS.

Ardelyx (NASDAQ:ARDX - Get Free Report) last announced its earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.02. Ardelyx had a negative net margin of 11.73% and a negative return on equity of 24.87%. The firm had revenue of $116.13 million for the quarter, compared to analyst estimates of $111.16 million.

ARDX has been the topic of a number of other research reports. Raymond James reaffirmed a "strong-buy" rating and set a $13.00 price target (down previously from $15.00) on shares of Ardelyx in a research note on Friday, February 21st. Piper Sandler upgraded Ardelyx to a "hold" rating in a report on Wednesday, March 12th. HC Wainwright reiterated a "neutral" rating and set a $5.50 target price on shares of Ardelyx in a report on Friday, February 21st. Cantor Fitzgerald upgraded shares of Ardelyx to a "strong-buy" rating in a research note on Tuesday, March 4th. Finally, Scotiabank started coverage on shares of Ardelyx in a research report on Friday, March 7th. They set a "sector outperform" rating and a $15.00 price target for the company. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $10.61.

Ardelyx Trading Up 0.4 %

NASDAQ:ARDX traded up $0.02 during mid-day trading on Friday, reaching $4.83. The company's stock had a trading volume of 2,215,454 shares, compared to its average volume of 4,374,028. Ardelyx has a twelve month low of $4.02 and a twelve month high of $9.33. The company's fifty day simple moving average is $5.09 and its two-hundred day simple moving average is $5.30. The company has a debt-to-equity ratio of 0.87, a current ratio of 4.58 and a quick ratio of 4.31. The stock has a market cap of $1.15 billion, a P/E ratio of -30.19 and a beta of 0.81.

Hedge Funds Weigh In On Ardelyx

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Janus Henderson Group PLC increased its position in Ardelyx by 13.3% in the fourth quarter. Janus Henderson Group PLC now owns 24,387,941 shares of the biopharmaceutical company's stock worth $123,587,000 after buying an additional 2,858,061 shares during the period. Two Seas Capital LP acquired a new stake in shares of Ardelyx in the 4th quarter worth about $9,407,000. Rock Springs Capital Management LP bought a new stake in Ardelyx in the 4th quarter valued at about $7,421,000. D. E. Shaw & Co. Inc. boosted its stake in Ardelyx by 9,499.8% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,468,668 shares of the biopharmaceutical company's stock valued at $7,446,000 after purchasing an additional 1,453,369 shares during the period. Finally, Point72 Asset Management L.P. bought a new position in Ardelyx in the 4th quarter worth about $6,762,000. 58.92% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CFO Justin A. Renz sold 5,171 shares of the firm's stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $5.62, for a total value of $29,061.02. Following the transaction, the chief financial officer now directly owns 285,968 shares in the company, valued at approximately $1,607,140.16. This trade represents a 1.78 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Michael Raab sold 41,666 shares of Ardelyx stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $5.36, for a total transaction of $223,329.76. Following the completion of the transaction, the chief executive officer now directly owns 1,108,719 shares of the company's stock, valued at $5,942,733.84. This trade represents a 3.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 158,076 shares of company stock valued at $823,804 in the last ninety days. Corporate insiders own 5.90% of the company's stock.

Ardelyx Company Profile

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.